| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epilepsy | 61 | 2024 | 423 | 12.420 |
Why?
|
| Electroencephalography | 62 | 2024 | 749 | 9.890 |
Why?
|
| Seizures | 41 | 2024 | 306 | 6.990 |
Why?
|
| Seizures, Febrile | 20 | 2024 | 25 | 3.900 |
Why?
|
| Anticonvulsants | 27 | 2023 | 125 | 3.770 |
Why?
|
| Epilepsies, Myoclonic | 8 | 2024 | 18 | 3.720 |
Why?
|
| Status Epilepticus | 19 | 2024 | 35 | 3.140 |
Why?
|
| Infant | 64 | 2024 | 3147 | 2.660 |
Why?
|
| Spasms, Infantile | 10 | 2024 | 35 | 2.600 |
Why?
|
| Diet, Ketogenic | 7 | 2024 | 13 | 2.350 |
Why?
|
| Epilepsies, Partial | 15 | 2020 | 42 | 2.280 |
Why?
|
| Epilepsy, Generalized | 7 | 2023 | 40 | 2.170 |
Why?
|
| Child | 69 | 2024 | 7149 | 2.170 |
Why?
|
| Child, Preschool | 57 | 2024 | 3717 | 1.990 |
Why?
|
| Epileptic Syndromes | 2 | 2023 | 8 | 1.800 |
Why?
|
| Ketosis | 7 | 2022 | 9 | 1.710 |
Why?
|
| Brain Diseases | 5 | 2023 | 185 | 1.690 |
Why?
|
| Epilepsy, Absence | 4 | 2024 | 10 | 1.480 |
Why?
|
| Myoclonus | 5 | 2023 | 16 | 1.440 |
Why?
|
| Humans | 143 | 2024 | 89063 | 1.420 |
Why?
|
| Magnetic Resonance Imaging | 23 | 2024 | 3443 | 1.410 |
Why?
|
| Lennox Gastaut Syndrome | 3 | 2024 | 15 | 1.200 |
Why?
|
| Developmental Disabilities | 5 | 2023 | 202 | 1.090 |
Why?
|
| Epilepsy, Temporal Lobe | 6 | 2024 | 131 | 1.080 |
Why?
|
| Drug Resistant Epilepsy | 3 | 2023 | 51 | 1.050 |
Why?
|
| Brain | 16 | 2024 | 2281 | 1.020 |
Why?
|
| Electrocorticography | 3 | 2024 | 45 | 1.000 |
Why?
|
| Epilepsy, Tonic-Clonic | 2 | 2020 | 8 | 0.980 |
Why?
|
| Female | 76 | 2024 | 46011 | 0.960 |
Why?
|
| Brain Waves | 3 | 2013 | 32 | 0.950 |
Why?
|
| Infant, Newborn | 22 | 2022 | 2476 | 0.940 |
Why?
|
| Male | 70 | 2024 | 42251 | 0.910 |
Why?
|
| Dystonia | 2 | 2023 | 29 | 0.910 |
Why?
|
| Nerve Tissue Proteins | 3 | 2020 | 511 | 0.880 |
Why?
|
| Dystonic Disorders | 1 | 2023 | 7 | 0.870 |
Why?
|
| Basal Ganglia | 1 | 2023 | 46 | 0.860 |
Why?
|
| Neurosurgical Procedures | 4 | 2024 | 232 | 0.840 |
Why?
|
| Cerebellar Ataxia | 1 | 2022 | 22 | 0.840 |
Why?
|
| Piracetam | 2 | 2015 | 8 | 0.840 |
Why?
|
| Intelligence | 3 | 2015 | 71 | 0.820 |
Why?
|
| Retrospective Studies | 30 | 2024 | 9003 | 0.800 |
Why?
|
| Adolescent | 31 | 2024 | 9237 | 0.770 |
Why?
|
| Frailty | 1 | 2022 | 76 | 0.760 |
Why?
|
| Neurology | 2 | 2021 | 74 | 0.740 |
Why?
|
| Pediatrics | 4 | 2013 | 352 | 0.730 |
Why?
|
| Cerebral Cortex | 10 | 2014 | 589 | 0.730 |
Why?
|
| Hippocampus | 10 | 2024 | 447 | 0.640 |
Why?
|
| Epilepsy, Rolandic | 2 | 2016 | 2 | 0.630 |
Why?
|
| Potassium Channels | 1 | 2020 | 343 | 0.620 |
Why?
|
| Hashimoto Disease | 1 | 2017 | 11 | 0.610 |
Why?
|
| Syndrome | 11 | 2016 | 449 | 0.610 |
Why?
|
| Cognition Disorders | 3 | 2012 | 235 | 0.600 |
Why?
|
| Proteins | 1 | 2023 | 786 | 0.590 |
Why?
|
| Mutation | 7 | 2023 | 4132 | 0.590 |
Why?
|
| Eye | 1 | 2017 | 111 | 0.580 |
Why?
|
| Brain Mapping | 5 | 2024 | 564 | 0.570 |
Why?
|
| Carbamazepine | 2 | 2015 | 9 | 0.570 |
Why?
|
| Intraoperative Neurophysiological Monitoring | 1 | 2017 | 12 | 0.570 |
Why?
|
| Ketone Bodies | 3 | 2022 | 16 | 0.560 |
Why?
|
| Treatment Outcome | 19 | 2024 | 8203 | 0.560 |
Why?
|
| Muscle Weakness | 1 | 2016 | 60 | 0.540 |
Why?
|
| Hypothyroidism | 1 | 2017 | 238 | 0.520 |
Why?
|
| Pyridoxine | 1 | 2015 | 3 | 0.520 |
Why?
|
| Social Skills | 1 | 2015 | 8 | 0.510 |
Why?
|
| Child Behavior | 1 | 2015 | 47 | 0.490 |
Why?
|
| Dietary Fats | 5 | 2007 | 135 | 0.490 |
Why?
|
| Muscle, Skeletal | 1 | 2017 | 466 | 0.470 |
Why?
|
| Monitoring, Intraoperative | 2 | 2014 | 110 | 0.470 |
Why?
|
| Intracranial Hemorrhages | 1 | 2015 | 129 | 0.470 |
Why?
|
| Age Factors | 14 | 2010 | 1867 | 0.460 |
Why?
|
| Central Nervous System Infections | 1 | 2013 | 3 | 0.460 |
Why?
|
| NAV1.1 Voltage-Gated Sodium Channel | 5 | 2023 | 7 | 0.450 |
Why?
|
| Epilepsy, Reflex | 2 | 2023 | 7 | 0.450 |
Why?
|
| Video Recording | 10 | 2023 | 203 | 0.430 |
Why?
|
| Diet, High-Protein Low-Carbohydrate | 2 | 2023 | 4 | 0.430 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2012 | 39 | 0.420 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2012 | 65 | 0.410 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2012 | 49 | 0.410 |
Why?
|
| Migraine Disorders | 1 | 2012 | 40 | 0.400 |
Why?
|
| Fatigue | 1 | 2012 | 179 | 0.390 |
Why?
|
| Stroke | 2 | 2023 | 982 | 0.380 |
Why?
|
| Terminology as Topic | 5 | 2017 | 221 | 0.380 |
Why?
|
| Frontal Lobe | 1 | 2012 | 131 | 0.380 |
Why?
|
| Reaction Time | 2 | 2012 | 310 | 0.370 |
Why?
|
| Genetic Loci | 1 | 2012 | 253 | 0.370 |
Why?
|
| Monitoring, Physiologic | 4 | 2006 | 266 | 0.370 |
Why?
|
| Linkage Disequilibrium | 1 | 2012 | 477 | 0.360 |
Why?
|
| International Agencies | 4 | 2017 | 35 | 0.360 |
Why?
|
| Biological Clocks | 1 | 2010 | 74 | 0.350 |
Why?
|
| Sodium Channels | 2 | 2009 | 129 | 0.350 |
Why?
|
| Pregabalin | 2 | 2020 | 6 | 0.350 |
Why?
|
| Nervous System Diseases | 1 | 2010 | 162 | 0.340 |
Why?
|
| Diagnosis, Differential | 9 | 2015 | 1591 | 0.330 |
Why?
|
| Memory, Short-Term | 1 | 2012 | 225 | 0.310 |
Why?
|
| Encephalitis | 3 | 2016 | 104 | 0.310 |
Why?
|
| Aging | 1 | 2013 | 716 | 0.300 |
Why?
|
| Myoclonic Epilepsy, Juvenile | 1 | 2007 | 2 | 0.290 |
Why?
|
| Spasm | 2 | 2024 | 17 | 0.290 |
Why?
|
| Patient Selection | 2 | 2001 | 682 | 0.280 |
Why?
|
| Vigabatrin | 2 | 2016 | 3 | 0.280 |
Why?
|
| Malformations of Cortical Development | 2 | 2017 | 39 | 0.270 |
Why?
|
| Causality | 2 | 2022 | 80 | 0.270 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 2016 | 131 | 0.270 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2023 | 94 | 0.270 |
Why?
|
| Phenotype | 3 | 2012 | 2439 | 0.270 |
Why?
|
| Time Factors | 11 | 2020 | 5320 | 0.260 |
Why?
|
| Ocular Physiological Phenomena | 1 | 2005 | 11 | 0.260 |
Why?
|
| Sclerosis | 2 | 2024 | 29 | 0.260 |
Why?
|
| Angelman Syndrome | 1 | 2005 | 7 | 0.260 |
Why?
|
| Delta Rhythm | 1 | 2005 | 19 | 0.260 |
Why?
|
| Temporal Lobe | 5 | 2022 | 176 | 0.250 |
Why?
|
| Subdural Space | 1 | 2024 | 17 | 0.240 |
Why?
|
| Psychosurgery | 2 | 2020 | 15 | 0.230 |
Why?
|
| Stereotaxic Techniques | 2 | 2024 | 80 | 0.230 |
Why?
|
| Age of Onset | 4 | 2007 | 312 | 0.230 |
Why?
|
| Eyelids | 4 | 2023 | 23 | 0.220 |
Why?
|
| Repressor Proteins | 2 | 2018 | 423 | 0.220 |
Why?
|
| Eye Diseases | 1 | 2023 | 58 | 0.220 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2002 | 30 | 0.220 |
Why?
|
| Research Design | 2 | 2020 | 597 | 0.210 |
Why?
|
| Knowledge | 1 | 2023 | 29 | 0.210 |
Why?
|
| Patient Care Team | 2 | 2008 | 283 | 0.210 |
Why?
|
| Ataxia | 1 | 2022 | 39 | 0.210 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2024 | 251 | 0.200 |
Why?
|
| Follow-Up Studies | 7 | 2024 | 3657 | 0.200 |
Why?
|
| Cognition | 2 | 2016 | 580 | 0.200 |
Why?
|
| Scalp | 1 | 2022 | 72 | 0.200 |
Why?
|
| Postoperative Period | 1 | 2022 | 301 | 0.200 |
Why?
|
| Social Media | 1 | 2023 | 93 | 0.190 |
Why?
|
| Graft vs Host Disease | 1 | 2023 | 360 | 0.180 |
Why?
|
| Videotape Recording | 3 | 2009 | 48 | 0.180 |
Why?
|
| Functional Laterality | 3 | 2012 | 200 | 0.180 |
Why?
|
| GTPase-Activating Proteins | 2 | 2018 | 67 | 0.180 |
Why?
|
| Death, Sudden | 2 | 2018 | 40 | 0.180 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 1715 | 0.180 |
Why?
|
| Neonatology | 1 | 2020 | 11 | 0.180 |
Why?
|
| Corpus Callosum | 1 | 2020 | 59 | 0.170 |
Why?
|
| Cohort Studies | 10 | 2016 | 2863 | 0.170 |
Why?
|
| Mental Disorders | 1 | 2004 | 412 | 0.170 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 202 | 0.170 |
Why?
|
| Adult | 15 | 2024 | 26507 | 0.170 |
Why?
|
| Valproic Acid | 2 | 1998 | 24 | 0.170 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2020 | 111 | 0.170 |
Why?
|
| Electrophysiological Phenomena | 1 | 2019 | 51 | 0.170 |
Why?
|
| Family | 1 | 2021 | 325 | 0.170 |
Why?
|
| Neocortex | 2 | 2019 | 96 | 0.170 |
Why?
|
| Electrodes, Implanted | 2 | 2024 | 177 | 0.170 |
Why?
|
| Drug Therapy, Combination | 4 | 2020 | 783 | 0.160 |
Why?
|
| Laser Therapy | 1 | 2020 | 149 | 0.160 |
Why?
|
| Administration, Oral | 3 | 2016 | 682 | 0.160 |
Why?
|
| Pulmonary Artery | 1 | 2020 | 319 | 0.160 |
Why?
|
| Risk Factors | 8 | 2017 | 5466 | 0.150 |
Why?
|
| Synaptic Transmission | 1 | 2019 | 228 | 0.150 |
Why?
|
| Prospective Studies | 10 | 2016 | 4273 | 0.150 |
Why?
|
| Preoperative Period | 1 | 2017 | 94 | 0.150 |
Why?
|
| Brain Damage, Chronic | 1 | 2017 | 26 | 0.150 |
Why?
|
| Fractures, Bone | 1 | 1998 | 127 | 0.140 |
Why?
|
| Genetic Testing | 2 | 2015 | 537 | 0.140 |
Why?
|
| Double-Blind Method | 4 | 2020 | 1714 | 0.140 |
Why?
|
| Cadherins | 1 | 2017 | 163 | 0.140 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 257 | 0.140 |
Why?
|
| Tissue Banks | 1 | 2016 | 16 | 0.140 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2018 | 287 | 0.140 |
Why?
|
| Neuroimaging | 4 | 2020 | 117 | 0.140 |
Why?
|
| Biomarkers | 3 | 2020 | 1755 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 889 | 0.130 |
Why?
|
| Consensus | 3 | 2023 | 356 | 0.130 |
Why?
|
| Artifacts | 1 | 2017 | 245 | 0.130 |
Why?
|
| Torsion Abnormality | 1 | 2015 | 17 | 0.130 |
Why?
|
| Treatment Failure | 1 | 2016 | 287 | 0.130 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2015 | 15 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 2 | 2015 | 1043 | 0.130 |
Why?
|
| Biomedical Research | 1 | 2020 | 398 | 0.130 |
Why?
|
| Vitamin B Complex | 1 | 2015 | 21 | 0.130 |
Why?
|
| Injections, Intravenous | 1 | 2015 | 240 | 0.130 |
Why?
|
| Pilot Projects | 2 | 2015 | 865 | 0.130 |
Why?
|
| Cytokines | 2 | 2017 | 802 | 0.120 |
Why?
|
| Language | 1 | 2016 | 154 | 0.120 |
Why?
|
| Fetomaternal Transfusion | 1 | 1994 | 2 | 0.120 |
Why?
|
| Sequence Deletion | 1 | 2015 | 205 | 0.120 |
Why?
|
| Parents | 3 | 2012 | 285 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1149 | 0.120 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2015 | 52 | 0.120 |
Why?
|
| Memory | 1 | 2016 | 220 | 0.120 |
Why?
|
| Hypothermia, Induced | 1 | 2015 | 82 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2016 | 266 | 0.120 |
Why?
|
| Head | 1 | 2015 | 135 | 0.120 |
Why?
|
| Brain Stem | 1 | 2015 | 167 | 0.120 |
Why?
|
| Gestational Age | 1 | 2015 | 323 | 0.120 |
Why?
|
| Reproducibility of Results | 3 | 2015 | 2752 | 0.120 |
Why?
|
| Cerebral Infarction | 1 | 1994 | 72 | 0.120 |
Why?
|
| Neuropsychological Tests | 2 | 2016 | 505 | 0.120 |
Why?
|
| Intellectual Disability | 2 | 2012 | 189 | 0.120 |
Why?
|
| International Cooperation | 3 | 2009 | 125 | 0.110 |
Why?
|
| Disease Management | 3 | 2015 | 329 | 0.110 |
Why?
|
| Psychometrics | 1 | 2015 | 329 | 0.110 |
Why?
|
| Length of Stay | 1 | 2017 | 732 | 0.110 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2015 | 491 | 0.110 |
Why?
|
| Biological Ontologies | 1 | 2013 | 3 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2020 | 1940 | 0.110 |
Why?
|
| Herpesvirus 7, Human | 1 | 2012 | 3 | 0.110 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 1837 | 0.100 |
Why?
|
| Roseolovirus Infections | 1 | 2012 | 7 | 0.100 |
Why?
|
| Herpesvirus 6, Human | 1 | 2012 | 19 | 0.100 |
Why?
|
| Wechsler Scales | 1 | 2012 | 21 | 0.100 |
Why?
|
| Mental Processes | 1 | 2012 | 31 | 0.100 |
Why?
|
| Sleep Wake Disorders | 1 | 2012 | 117 | 0.100 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2011 | 5 | 0.100 |
Why?
|
| Prognosis | 3 | 2007 | 3773 | 0.100 |
Why?
|
| Autistic Disorder | 1 | 2012 | 150 | 0.100 |
Why?
|
| Odds Ratio | 2 | 2013 | 684 | 0.100 |
Why?
|
| Evidence-Based Medicine | 2 | 2017 | 433 | 0.090 |
Why?
|
| Quality of Life | 2 | 2015 | 1662 | 0.090 |
Why?
|
| Disease Progression | 1 | 2015 | 1488 | 0.090 |
Why?
|
| Emergency Medical Services | 1 | 2014 | 238 | 0.090 |
Why?
|
| Acute Disease | 1 | 2012 | 841 | 0.090 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2011 | 202 | 0.090 |
Why?
|
| Postoperative Complications | 2 | 2017 | 2275 | 0.090 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2011 | 87 | 0.090 |
Why?
|
| Ganglioglioma | 1 | 2010 | 4 | 0.090 |
Why?
|
| Fructose | 1 | 2010 | 36 | 0.090 |
Why?
|
| Family Health | 2 | 2013 | 162 | 0.080 |
Why?
|
| Drug Evaluation | 1 | 2009 | 138 | 0.080 |
Why?
|
| Child Development | 1 | 2011 | 167 | 0.080 |
Why?
|
| Comorbidity | 2 | 2017 | 948 | 0.080 |
Why?
|
| Confidence Intervals | 1 | 2009 | 225 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 2335 | 0.080 |
Why?
|
| Diet, Carbohydrate-Restricted | 2 | 2023 | 4 | 0.070 |
Why?
|
| Mass Screening | 1 | 2012 | 636 | 0.070 |
Why?
|
| Heart Arrest | 1 | 2011 | 279 | 0.070 |
Why?
|
| Fasting | 1 | 2007 | 163 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 894 | 0.070 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2007 | 22 | 0.070 |
Why?
|
| Health Education | 1 | 2007 | 105 | 0.070 |
Why?
|
| Vagus Nerve | 1 | 2007 | 49 | 0.070 |
Why?
|
| Genotype | 2 | 2018 | 1848 | 0.070 |
Why?
|
| Preoperative Care | 2 | 2006 | 396 | 0.070 |
Why?
|
| Electric Stimulation Therapy | 1 | 2007 | 46 | 0.070 |
Why?
|
| MELAS Syndrome | 1 | 2006 | 5 | 0.070 |
Why?
|
| Animals | 6 | 2018 | 27317 | 0.070 |
Why?
|
| Otitis Media | 1 | 2005 | 20 | 0.070 |
Why?
|
| Telemetry | 1 | 2006 | 36 | 0.060 |
Why?
|
| Aortic Rupture | 1 | 2006 | 57 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2005 | 66 | 0.060 |
Why?
|
| Databases as Topic | 1 | 2005 | 94 | 0.060 |
Why?
|
| DNA Mutational Analysis | 1 | 2007 | 529 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2009 | 948 | 0.060 |
Why?
|
| Referral and Consultation | 2 | 2006 | 341 | 0.060 |
Why?
|
| Pedigree | 2 | 2018 | 969 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 485 | 0.060 |
Why?
|
| Electrodes | 1 | 2024 | 88 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2010 | 781 | 0.060 |
Why?
|
| Surveys and Questionnaires | 3 | 2013 | 2612 | 0.060 |
Why?
|
| Appointments and Schedules | 1 | 2004 | 54 | 0.060 |
Why?
|
| Atrophy | 1 | 2024 | 119 | 0.060 |
Why?
|
| Clinical Protocols | 1 | 2004 | 157 | 0.060 |
Why?
|
| Tomography, Emission-Computed | 2 | 2001 | 102 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2016 | 590 | 0.060 |
Why?
|
| Sex Factors | 1 | 2006 | 1063 | 0.060 |
Why?
|
| Neurologic Examination | 2 | 2012 | 120 | 0.050 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2003 | 73 | 0.050 |
Why?
|
| Logistic Models | 1 | 2006 | 1212 | 0.050 |
Why?
|
| Smartphone | 1 | 2023 | 39 | 0.050 |
Why?
|
| Ion Channels | 1 | 2004 | 246 | 0.050 |
Why?
|
| Central Nervous System | 1 | 2023 | 153 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2023 | 188 | 0.050 |
Why?
|
| Automatism | 1 | 2001 | 1 | 0.050 |
Why?
|
| Diet Therapy | 1 | 2001 | 20 | 0.050 |
Why?
|
| Incidence | 1 | 2005 | 1592 | 0.050 |
Why?
|
| Sick Role | 1 | 2001 | 13 | 0.050 |
Why?
|
| Food, Formulated | 2 | 1998 | 24 | 0.050 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2014 | 302 | 0.050 |
Why?
|
| Action Potentials | 1 | 2024 | 596 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2001 | 166 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2020 | 92 | 0.040 |
Why?
|
| Societies, Scientific | 1 | 2020 | 43 | 0.040 |
Why?
|
| Diffusion of Innovation | 1 | 2020 | 71 | 0.040 |
Why?
|
| Cerebral Hemorrhage | 1 | 2023 | 338 | 0.040 |
Why?
|
| Nutritional Status | 1 | 1999 | 80 | 0.040 |
Why?
|
| Communication | 1 | 2023 | 457 | 0.040 |
Why?
|
| United Kingdom | 1 | 2019 | 164 | 0.040 |
Why?
|
| Carnitine | 1 | 1998 | 14 | 0.040 |
Why?
|
| Forecasting | 1 | 2020 | 305 | 0.040 |
Why?
|
| Brugada Syndrome | 1 | 2018 | 14 | 0.040 |
Why?
|
| INDEL Mutation | 1 | 2018 | 31 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2018 | 29 | 0.040 |
Why?
|
| Femoral Fractures | 1 | 1998 | 27 | 0.040 |
Why?
|
| Tibial Fractures | 1 | 1998 | 36 | 0.040 |
Why?
|
| Foot | 1 | 1998 | 52 | 0.040 |
Why?
|
| Dominance, Cerebral | 2 | 1996 | 66 | 0.040 |
Why?
|
| Plethysmography | 1 | 2018 | 18 | 0.040 |
Why?
|
| Hypoventilation | 1 | 2018 | 6 | 0.040 |
Why?
|
| Loss of Function Mutation | 1 | 2018 | 46 | 0.040 |
Why?
|
| Receptors, Muscarinic | 1 | 2018 | 48 | 0.040 |
Why?
|
| Hip Fractures | 1 | 1998 | 46 | 0.040 |
Why?
|
| Bradycardia | 1 | 2018 | 40 | 0.040 |
Why?
|
| Parasympathetic Nervous System | 1 | 2018 | 36 | 0.040 |
Why?
|
| Multiprotein Complexes | 1 | 2018 | 96 | 0.040 |
Why?
|
| Muscarinic Antagonists | 1 | 2018 | 58 | 0.040 |
Why?
|
| Respiration Disorders | 1 | 2018 | 41 | 0.040 |
Why?
|
| Citric Acid Cycle | 1 | 1997 | 21 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2001 | 359 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 1998 | 200 | 0.040 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2017 | 12 | 0.040 |
Why?
|
| Mice, Inbred C3H | 1 | 2018 | 371 | 0.040 |
Why?
|
| Electromyography | 1 | 2018 | 193 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 177 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 2017 | 86 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 82 | 0.040 |
Why?
|
| Bone and Bones | 1 | 1998 | 269 | 0.040 |
Why?
|
| Young Adult | 3 | 2015 | 6288 | 0.040 |
Why?
|
| Gliosis | 1 | 1996 | 35 | 0.040 |
Why?
|
| Diet | 1 | 1999 | 442 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2020 | 570 | 0.030 |
Why?
|
| Amygdala | 1 | 1996 | 86 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2017 | 261 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2016 | 102 | 0.030 |
Why?
|
| Glucose | 2 | 2012 | 630 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2015 | 39 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 850 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2018 | 493 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2018 | 352 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2015 | 88 | 0.030 |
Why?
|
| Occipital Lobe | 1 | 1994 | 24 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 360 | 0.030 |
Why?
|
| Astrocytes | 2 | 2009 | 141 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2008 | 1710 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 848 | 0.030 |
Why?
|
| Parietal Lobe | 1 | 1994 | 119 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 695 | 0.030 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2012 | 9 | 0.030 |
Why?
|
| Leukocytosis | 1 | 2012 | 16 | 0.030 |
Why?
|
| Spinal Puncture | 1 | 2012 | 37 | 0.030 |
Why?
|
| Reference Standards | 1 | 2012 | 144 | 0.030 |
Why?
|
| Tuberous Sclerosis | 1 | 2012 | 28 | 0.030 |
Why?
|
| Mitochondrial Diseases | 1 | 2012 | 12 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 1994 | 271 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 130 | 0.020 |
Why?
|
| Prevalence | 1 | 2016 | 1240 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2012 | 280 | 0.020 |
Why?
|
| Patients | 1 | 2012 | 102 | 0.020 |
Why?
|
| Sleep Stages | 1 | 1991 | 47 | 0.020 |
Why?
|
| Leukocytes | 1 | 2012 | 204 | 0.020 |
Why?
|
| Papio | 1 | 1991 | 82 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2015 | 685 | 0.020 |
Why?
|
| Pregnancy | 2 | 1996 | 3009 | 0.020 |
Why?
|
| Rats | 1 | 1997 | 4040 | 0.020 |
Why?
|
| Observer Variation | 1 | 2012 | 610 | 0.020 |
Why?
|
| Internet | 1 | 2012 | 318 | 0.020 |
Why?
|
| Fetus | 1 | 1991 | 232 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 582 | 0.020 |
Why?
|
| Neuroimmunomodulation | 1 | 2009 | 11 | 0.020 |
Why?
|
| Microglia | 1 | 2009 | 107 | 0.020 |
Why?
|
| Cell Death | 1 | 2009 | 262 | 0.020 |
Why?
|
| Contraindications | 1 | 2008 | 70 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2013 | 1855 | 0.020 |
Why?
|
| Middle Aged | 2 | 2020 | 25863 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2008 | 232 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2008 | 125 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2018 | 3373 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2007 | 270 | 0.020 |
Why?
|
| Surgicenters | 1 | 2006 | 5 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2012 | 1239 | 0.020 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2005 | 10 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2006 | 147 | 0.020 |
Why?
|
| Surgery Department, Hospital | 1 | 2006 | 44 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2005 | 150 | 0.020 |
Why?
|
| Gastrostomy | 1 | 2006 | 69 | 0.020 |
Why?
|
| Specialties, Surgical | 1 | 2006 | 65 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2006 | 299 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2005 | 306 | 0.020 |
Why?
|
| Point Mutation | 1 | 2006 | 245 | 0.020 |
Why?
|
| Physicians | 1 | 2012 | 689 | 0.020 |
Why?
|
| Fever | 1 | 2005 | 128 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 2006 | 354 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1994 | 2657 | 0.010 |
Why?
|
| Mice | 1 | 2018 | 11737 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 921 | 0.010 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2003 | 20 | 0.010 |
Why?
|
| United States | 1 | 2016 | 6955 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2007 | 1067 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2003 | 100 | 0.010 |
Why?
|
| Evoked Potentials | 1 | 2003 | 190 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 1796 | 0.010 |
Why?
|
| Neurons | 1 | 2009 | 1580 | 0.010 |
Why?
|
| Erythrocyte Count | 1 | 1999 | 22 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 1 | 1999 | 34 | 0.010 |
Why?
|
| Hematocrit | 1 | 1999 | 68 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 1999 | 71 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 1999 | 74 | 0.010 |
Why?
|
| Platelet Count | 1 | 1999 | 93 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 1999 | 132 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1999 | 223 | 0.010 |
Why?
|
| Phosphorus | 1 | 1999 | 117 | 0.010 |
Why?
|
| Body Height | 1 | 1999 | 100 | 0.010 |
Why?
|
| Serum Albumin | 1 | 1999 | 127 | 0.010 |
Why?
|
| Hemoglobins | 1 | 1999 | 192 | 0.010 |
Why?
|
| Creatinine | 1 | 1999 | 293 | 0.010 |
Why?
|
| Ammonia | 1 | 1998 | 38 | 0.010 |
Why?
|
| Body Weight | 1 | 1999 | 452 | 0.010 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 1998 | 66 | 0.010 |
Why?
|
| Cholesterol | 1 | 1999 | 357 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 1998 | 142 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 1998 | 193 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 1996 | 53 | 0.010 |
Why?
|
| Calcium | 1 | 1999 | 1172 | 0.010 |
Why?
|
| Biopsy | 1 | 1996 | 1182 | 0.010 |
Why?
|